[ad_1]
Israeli medical machine firm SoniVie, which is growing a proprietary answer to deal with hypertension, introduced immediately the completion of a $60 million sequence C financing spherical led by Andera Companions, with participation from Supernova Make investments and Omega Funds. Earlier SoniVie investor TechWald additionally participated.
SoniVie has additionally appointed two main medtech consultants to its board of administrators, Raymond W. Cohen and Zeev Zehavi, as impartial administrators.
RELATED ARTICLES
SoniVie completes first PAH catheter procedures
SoniVie has developed an ultrasound-based denervation know-how with software in a number of therapeutic areas. TIVUS (Therapeutic Intra-Vascular Ultrasound System) employs high-frequency non-focused ultrasound vitality to ablate nerves within the renal artery to lower blood stress. This minimally invasive investigational process can be utilized to deal with sufferers affected by hypertension, which impacts hundreds of thousands of individuals worldwide and considerably will increase their danger of coronary heart assault, stroke and kidney failure.
TIVUS has lively growth packages in three therapeutic areas: pulmonary artery denervation for pulmonary hypertension, renal artery denervation for resistant hypertension, and lung denervation for continual obstructive pulmonary illness with continual bronchitis.
SoniVie will use the brand new financing to achieve scientific and regulatory milestones and to assist its TIVUS renal artery denervation program.
SoniVie CEO Tomaso Zambelli mentioned, “We’re very happy that this financing spherical concluded with such a convincing success. The brand new traders and the Board of Administrators carry important expertise to the Firm within the area of Renal Denervation for Hypertension.”
Printed by Globes, Israel enterprise information – en.globes.co.il – on January 9, 2023.
© Copyright of Globes Writer Itonut (1983) Ltd., 2023.
[ad_2]
Source link
